At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
In Brief
A Phase 2 clinical trial evaluating Docetaxel, Feladilimab, and 4 other interventions for Neoplasms. Completed, enrolled 175 participants across 57 sites in 12 countries.
Detailed Summary
This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II open-label part comparing the efficacy and safety of these novel regimens with SoC. Drug name mentioned as GSK4428859A (belrestotug) and EOS884448 are interchangeable for the same compound and will be referred to as GSK4428859A/EOS884448/belrestotug.
Study Details
Timeline
Interventions
Docetaxel will be administered.
Feladilimab will be administered.
Ipilimumab will be administered.
GSK4428859A/EOS884448 will be administered.
Dostarlimab will be administered.
GSK6097608 will be administered.